VERISMO
This is a prospective, non-interventional, longitudinal, observational study of MS patients who have newly initiated treatment with ocrelizumab that is being conducted to determine the incidence and mortality rates of breast cancer and all malignancies.
Type: Observational
Principal Investigator: Matthew Tremblay, MD, PhD
Website: ClinicalTrials.gov Identifier:
This study is active, and open for enrollment.
For inquiries, call
(973) 322-7073
